GCGR and Other metabolic disease: Worth to mention: (1) the important advances in the development of new lipid-lowering and antiobesity drugs with very different mechanisms of action, including the development of dual or triagonists of the GIP, GLP-1, and/or glucagon receptors (GIPR/GLP-1R/GCGR) in the treatment of metabolic diseases and the combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide (CagriSema); (2) the progressive increase in biological medications [antisense oligonucleotides (ASOs), siRNAs, and monoclonal antibodies (mAb)] and small molecules under development.